| References: |
CHR-2797 is an aminopeptidase inhibitor, with IC50 values of 100 nM for LAP3 (LAP), 150 nM for PSAP (PuSA) and 220 nM for CD13 (Aminopeptidase N). CHR-2797 is converted in cells to the active acid metabolite, CHR-79888, which is a significant inhibitor of Leukotriene A4 hydrolase with an IC50 of 8 nM. CHR-2797 exhibits profound anti-proliferative effects against a range of cancer cell lines such as U-937, HL-60, KG-1 and GDM-1. For the detailed information of Tosedostat (CHR2797), the solubility of Tosedostat (CHR2797) in water, the solubility of Tosedostat (CHR2797) in DMSO, the solubility of Tosedostat (CHR2797) in PBS buffer, the animal experiment (test) of Tosedostat (CHR2797), the cell expriment (test) of Tosedostat (CHR2797), the in vivo, in vitro and clinical trial test of Tosedostat (CHR2797), the EC50, IC50,and affinity,of Tosedostat (CHR2797), For the detailed information of Tosedostat (CHR2797), the solubility of Tosedostat (CHR2797) in water, the solubility of Tosedostat (CHR2797) in DMSO, the solubility of Tosedostat (CHR2797) in PBS buffer, the animal experiment (test) of Tosedostat (CHR2797), the cell expriment (test) of Tosedostat (CHR2797), the in vivo, in vitro and clinical trial test of Tosedostat (CHR2797), the EC50, IC50,and affinity,of Tosedostat (CHR2797), Please contact DC Chemicals. |
